Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors
Related Experiment Video
Updated: Oct 2, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
R Haddad1, K E Lipson, C P Webb
1Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Abstract:
Hepatocyte growth factor/Scatter Factor (HGF/SF) mediated stimulation of the Met receptor tyrosine kinase results in pleiotropic cellular effects including proliferation, morphogenesis, motility and invasion. In vivo, HGF/SF-Met activation has been shown to participate in tumorigenesis, angiogenesis and metastasis. Coupled with accumulating evidence that aberrant HGF/SF-Met expression is frequently observed in a variety of human tumors, often in association with progressive disease, these data present HGF/SF-Met as an attractive target for therapeutic intervention in human cancer. In this review, we will present the most compelling evidence suggesting a key role for HGF/SF-Met signaling in tumorigenesis, and discuss several possible therapeutic strategies.
Insights
Hepatocyte growth factor/Scatter Factor (HGF/SF) and Met receptor signaling drive cancer progression. Targeting this pathway offers a promising therapeutic strategy for various human tumors.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Hepatocyte growth factor/Scatter Factor (HGF/SF) activates the Met receptor tyrosine kinase.
- This activation leads to diverse cellular responses like proliferation, motility, and invasion.
- Aberrant HGF/SF-Met signaling is implicated in tumorigenesis, angiogenesis, and metastasis.
Purpose of the Study:
- To review the critical role of HGF/SF-Met signaling in cancer development.
- To discuss the therapeutic potential of targeting the HGF/SF-Met pathway in human cancers.
Main Methods:
- Literature review of existing studies on HGF/SF-Met signaling in cancer.
- Analysis of evidence linking HGF/SF-Met expression to tumor progression and metastasis.
Main Results:
- Compelling evidence supports a key role for HGF/SF-Met signaling in tumorigenesis.
- Frequent aberrant HGF/SF-Met expression correlates with progressive disease in various human tumors.
Conclusions:
- The HGF/SF-Met pathway is a significant driver of cancer.
- Targeting HGF/SF-Met represents a viable therapeutic strategy for cancer intervention.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Healing I: Introduction